Characterization of thymic masses using (18)F-FDG PET-CT

Area of Science:

• Oncology
• Nuclear Medicine
• Diagnostic Imaging

Background:

• Accurate diagnosis and staging of thymic masses are crucial for treatment planning.
• Multimodality therapy can improve resectability and survival in thymoma and thymic carcinoma.
• Conventional imaging modalities have limitations in fully characterizing thymic lesions.

Purpose of the Study:

• To evaluate the utility of Fluorodeoxyglucose (FDG) Positron Emission Tomography-Computed Tomography (PET-CT) in differentiating various thymic lesions.
• To assess if FDG PET-CT can aid in the preoperative staging of thymic masses.
• To compare FDG uptake patterns in thymic hyperplasia, thymoma, and thymic carcinoma.

Main Methods:

• A prospective study involving 23 patients with anterior mediastinal masses suspicious for thymic origin.
• Whole-body FDG PET-CT was performed after intravenous injection of FDG.
• PET-CT interpretation included FDG uptake, SUVmax, pattern, invasion, metastasis, and necrosis, correlated with histopathology.

Main Results:

• Thymic hyperplasia showed a mean SUVmax of 1.1.
• Thymoma exhibited a mean SUVmax of 2.3 (low risk: 3, high risk: 2.1).
• Thymic carcinoma presented with a higher mean SUVmax of 7, with statistically significant differences observed between the groups.

Conclusions:

• (18)F-FDG PET-CT is a valuable tool for characterizing thymic lesions identified by conventional imaging.
• FDG PET-CT can assist in differentiating thymic hyperplasia, thymoma, and thymic carcinoma.
• Larger prospective studies are necessary to validate these findings and establish definitive diagnostic criteria.